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In spite of frequent discussions of misuse and misunderstanding of probability values (P-values) they still
appear in most scientiﬁc publications, and the disadvantages of erroneous and simplistic P-value
interpretations grow with the number of scientiﬁc publications. Osteoarthritis and Cartilage prefer
conﬁdence intervals. This is a brief discussion of problems surrounding P-values and conﬁdence intervals.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Probability values (P-values) seem to be the solid foundation on
which scientiﬁc progress relies. They appear in almost every epide-
miological, clinical, and pre-clinical research publication, either as
precise decimal numbers, inequalities (P > 0.05 and P < 0.05) or
as symbols (***, **, *, and NS). Several scientiﬁc arguments criti-
cizing this P-value culture have been published1. This criticism
can, in fact, be traced as far back as to 19332. Attempts to demolish
the culture have usually been futile3, and the problems of the
P-value culture are growing with the increasing number of scien-
tiﬁc publications. Osteoarthritis and Cartilage recommends pre-
senting sampling uncertainty in the form of conﬁdence intervals.
This is a brief presentation of the weaknesses of P-values and
strengths of conﬁdence intervals.
First, the aim of a scientiﬁc study or experiment is wider than
just to observe, because it is required of scientiﬁc results that
they can be generalized to other patients or cells than only those
examined or experimented on. One difference between quantita-
tive scientiﬁc research and other forms of investigations is that
the research work includes quantiﬁcation of the uncertainty of
the results.
The principle behind the uncertainty evaluation is to consider
the studied patients, or cells, as a random sample from an inﬁnite
population of patients, or cells. Statistical methods that assess the
sampling uncertainty have been the foundation for quantitative
medical research4 since the end of the second world war. The
resulting P-values and conﬁdence intervals contain information
on the sampling uncertainty of a ﬁnding, which inﬂuences the
generalizability of the results of the individual experiment study.
It is important to understand that these measures of generaliza-
tion uncertainty have no relevance for the studied sample itself, i.e.,
the studied groups of patients, animals or cells from which the
generalization is made. P-values and conﬁdence intervals guidetribution; df, degrees of
Research Society International. Puus in the uncertainty of whether an observed difference is a random
phenomenon, appearing just in the studied sample, or if it repre-
sents a true difference in the entire (unobserved) population,
from which the sample has been drawn and can be expected to
be a reproducible ﬁnding. The statistical precision section below
describes how the uncertainty can be quantiﬁed.
The current tradition in medical research of screening variables
with hypothesis tests to categorize ﬁndings either as statistically
signiﬁcant or insigniﬁcant is a simplistic and counter productive
analysis strategy that should be abandoned. This brief editorial
attempts to explain why.Statistical precision
Statistical precision has two determinants, the number of obser-
vations in the sample and the observations’ variability. These deter-
minants specify the standard error (SE) of an estimate such as the
mean:
SE[ SD=
ﬃﬃﬃ
n
p
where SD stands for standard deviation, and n is the number of
observations. Less variability and more observations reduce the
SE and increase the statistical precision.
When comparing the difference between two mean values, for
example to estimate the effect of the exposure to a speciﬁc agent
by comparing exposed with unexposed patient groups, the statis-
tical precision in the mean value difference, d (an observed differ-
ence), which also is an estimate of the effect from the exposure,
can be written:
SE[
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Where SD is the standard deviation common for both groups and n1
and n2 represent the number of independent observations in each
group.blished by Elsevier Ltd. All rights reserved.
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SE. When the studied difference, d, has a Gaussian distribution it
is statistically signiﬁcant at the 5% level when
jd=SEj>t0:05
Here t0.05 is the value in the Student’s t-distribution (introduced
in 1908 by William Gosset under the pseudonym Student) that
discriminates between the 95% jd/SEj having lower values and the
5% that have higher. Conversely, the conﬁdence interval
d t0:05SE
describes a range of plausible values in which the real effect is 95%
likely to be included.P-values
A P-value is the outcome from a hypothesis test of the null
hypothesis, H0: d ¼ 0. A low P-value indicates that observed data
do not match the null hypothesis, and when the P-value is lower
than the speciﬁed signiﬁcance level (usually 5%) the null hypothesis
is rejected, and the ﬁnding is considered statistically signiﬁcant.
The P-value has many weaknesses that needs to be recognized in
a successful analysis strategy.
First, the tested hypothesis should be deﬁned before inspecting
data. The P-value is not easily interpretable when the tested
hypothesis is deﬁned after data dredging, when a statistically
signiﬁcant outcome has been observed. If undisclosed to the reader
of a scientiﬁc report, such post-hoc testing is considered scientiﬁc
misconduct5.
Second, when multiple independent hypotheses are tested,
which usually is the case in a study or experiment, the risk that
at least one of these tests will be false positive increases, above
the nominal signiﬁcance level, with the number of hypotheses
tested. This multiplicity effect reduces the value of a statistically
signiﬁcant ﬁnding. Methods to adjust the overall signiﬁcance level
(like Bonferroni adjustment) exist, but the cost of such adjustments
is high. Either the number of observations has to be increased toFig. 1. Statistically and clinically signiﬁcant effects, measured in arbitrary unitcompensate for the adjustment, or the signiﬁcance level is main-
tained at the expense of the statistical power to detect an existing
effect or difference.
Third, a statistically insigniﬁcant difference between two
observed groups (the sample) does not indicate that this effect
does not exist in the population from which the sample is taken,
because the P-value is confounded by the number of observations;
it is based on the SE, which has On in the denominator. A statisti-
cally insigniﬁcant outcome indicates nothing more than that the
observed sample is too small to detect a population effect. A statis-
tically insigniﬁcant outcome should be interpreted as “absence of
evidence, not evidence of absence”6.
Fourth, for the same reason a statistically signiﬁcant effect in
a large sample can represent a real, but minute, clinically insignif-
icant, effect. For example, with sufﬁciently large sample size even
a painkiller reducing pain with as little as an average of 1 mm
VAS on a 100 mm scale will eventually demonstrate a highly statis-
tically signiﬁcant pain reduction. Any consideration of what consti-
tutes the lowest clinically signiﬁcant effect on pain would be
independent of sample size, perhaps depend on cost, and possibly
be related to the risk of side effects and availability of alternative
therapies.
Fifth, a P-value provides only uncertainty information vis-a-vis
a speciﬁc null hypothesis, no information on the statistical preci-
sion of an estimate. This means that comparisons with a lowest
clinically signiﬁcant effect (which may not be deﬁnable in labora-
tory experiments) cannot be based on P-values from conventional
hypothesis test. For example, a statistically signiﬁcant relative risk
of 2.1 observed in a sample can correspond to a relative risk of
1.1, as well as to one of 10.0, in the population. The statistical signif-
icance comes from the comparisonwith the null hypothesis relative
risk of 1.0. That one risk factor in the sample has lower P-value than
another one says nothing about their relative effect.
Sixth, when the tested null hypothesis is meaningless the
P-value will not be meaningful. For example, inter-observer reli-
ability is often presented with a P-value, but the null hypothesis
in this hypothesis test is that no inter-observer reliability exists.
However, why should two observers observing the same objects on an absolute scale, as evaluated by P-values and conﬁdence intervals.
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hypothesis to test using P-values. Showing the range of plausible
values of the inter-observer reliability in the population is much
more relevant.
Conﬁdence intervals
Conﬁdence intervals share some of the P-value’s weaknesses,
like the multiplicity problem, and analogous with the adjustment
of the signiﬁcance level, the width of conﬁdence intervals can
also be adjusted in cases of multiplicity. However, the great advan-
tage with conﬁdence intervals is that they do showwhat effects are
likely to exist in the population. Values excluded from the conﬁ-
dence interval are thus not likely to exist in the population. Conse-
quently, a conﬁdence interval excluding a speciﬁc effect can be
interpreted as providing evidence against the existence (in the
unobserved population) of such an effect. The conﬁdence interval
limits do thereby allow an easy and direct evaluation of clinical
signiﬁcance, see Fig. 1.
Conﬁdence interval limits are important criteria in the evalua-
tion of relative treatment effects in equivalence and non-
inferiority clinical trials, the trial designs used for testing if a new
drug at least is as good as an old one. The reasons for preferring
the new drug could be fewer side effects, lower cost, etc.
The margin of non-inferiority or equivalence introduces here
the notion of clinical signiﬁcance into randomized trial compar-
isons of treatment effect. By deﬁning what is a clinically signiﬁ-
cant difference in treatment effect it becomes possible to
evaluate non-inferiority, see Fig. 2. It is thus not sufﬁcient to
show statistical insigniﬁcance (again this indicates “absence of
evidence, not evidence of absence”), it is necessary to show clin-
ical insigniﬁcance with a conﬁdence interval narrow enough to
exclude clinically signiﬁcant effects (as this shows evidence of
absence).
The advantages of using conﬁdence intervals instead of P-values
has been frequently discussed in the literature1. In spite of this,Fig. 2. The use of conﬁdence intervals in superiority, non-inferiority andconﬁdence intervals are often misunderstood as representing vari-
ability of observations instead of uncertainty of the sample esti-
mate. Some further common misunderstandings should be
mentioned.
A consequence of the dominant P-value culture is that conﬁ-
dence intervals are often not appreciated by themselves, but the
information they convey are transformed into simplistic terms of
statistical signiﬁcance. For example, it is common to check if the
conﬁdence intervals of two mean values overlap. When this
happens, the difference of the mean values is often considered
statistically insigniﬁcant. However, Student’s t-test has a different
deﬁnition of the mean difference's standard error (SE) than what
is used in the calculation of the overlapping conﬁdence intervals.
Two means may well be statistically signiﬁcantly different and still
have somewhat overlapping conﬁdence intervals. Overlapping
conﬁdence intervals can therefore not be directly interpreted in
terms of statistical signiﬁcance7.
SEs are also often used to indicate uncertainty, as error bars in
graphical presentations. Using conﬁdence intervals is, however,
a better alternative because the uncertainty represented by a SE
is confounded by the number of observations8. For example, one
SE corresponds to a 58% conﬁdence interval when n is 3 and to
a 65% conﬁdence interval when n ¼ 9.
When pairwise multiple groups are compared with one and the
same reference or control group in terms of relative risk or odds
ratios, comparisons of conﬁdence intervals are only valid vis-a-vis
the reference group. However, conﬁdence intervals encourage
comparing effect sizes, and invalid comparisons are often made
between other groups. Assume, for example, that the knee replace-
ment revision risks of a low- (A) and a high (B) -exposed group of
smokers are compared with that of a group of non-smokers (C).
The three-group comparison leads to two relative risks, A/C and
B/C, both having conﬁdence intervals. These cannot be directly
compared; they depend on C. An alternative analysis method,
ﬂoating absolute risks (FAR), have been developed as a solution
to this problem9.equivalence trials, measured in arbitrary units on an absolute scale.
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continue to be important tools for interpreting scientiﬁc data.
Attempts to ban P-values from scientiﬁc journals have not been
successful10, and the aim of this discussion is not to stop authors
from using P-values. However, much can be gained by developing
the statistical analysis strategy of scientiﬁc studies. A better under-
standing of statistical inference and a more frequent use of conﬁ-
dence intervals are likely to play important roles in such
developments. This is not restricted to clinical research. The
phenomena discussed here are as important in laboratory
science8,11. Osteoarthritis and Cartilage recommends conﬁdence
interval as uncertainty measure in all studies12. More information
on this subject can be found in the guide for authors.Conﬂict of interest
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